Best Peptides for Longevity, UAE 2026
The three peptides with the strongest mechanistic case for longevity in 2026 are NAD+, GHK-Cu, and MOTS-C. Each targets a distinct biological pathway: cellular energy metabolism, collagen regeneration, and mitochondrial biogenesis respectively.
2024β2025 research links age-associated NAD+ depletion directly to sirtuin dysfunction, impaired DNA repair, and mitochondrial dysregulation. All three compounds are accessible to UAE-based researchers, though pricing, stock status, and regulatory standing vary significantly.
The sections below cover how each peptide works at the molecular level, which is most accessible in the UAE market, and what safety considerations apply to each.
| Peptide | Primary mechanism | Research dose range | Indicative price |
|---|---|---|---|
| NAD+ | Sirtuin activation, DNA repair | 250β1,000 mg per infusion | AED 1,395β2,200 (est.) |
| GHK-Cu | Collagen synthesis, wound healing | 0.01β2% topical; 1β10 mg injectable | Unverified AED price |
| MOTS-C | AMPK/PGC-1Ξ±, mitochondrial biogenesis | 5β20 mg subcutaneous (pilot data) | Unverified AED price |
Why Peptides Matter for Longevity Research
Longevity peptides are short-chain amino acid sequences that modulate specific biological pathways: cellular energy metabolism, connective tissue regeneration, and mitochondrial biogenesis. These pathways decline measurably with age. They are research compounds, not approved medicines, and their use outside controlled or specialist clinical settings carries regulatory and safety considerations that vary by jurisdiction.
Cellular Energy: NAD+ and Sirtuin Activation
NAD+ depletion is a documented driver of ageing at the molecular level. By the sixth decade of life, intracellular NAD+ concentrations fall to roughly half those measured in young adults, impairing sirtuin enzyme activity, slowing DNA repair, and destabilising mitochondrial membrane potential. Restoring NAD+ through direct administration or precursor supplementation reactivates SIRT1 and SIRT3, two sirtuins central to metabolic regulation and stress resistance.
The mechanism is specific: as intracellular NAD+ falls, SIRT1 and SIRT3 lose their substrate and become less active. Mitochondria accumulate damage, ATP output drops, and cells shift toward less efficient energy pathways. Restoring NAD+ availability reverses this cascade in preclinical models and correlates with improved metabolic flexibility in early human data.
Human IV protocols in 2024β2025 longevity research commonly deliver 250β750 mg per infusion to achieve measurable repletion. For researchers sourcing this compound locally, the NAD+ peptide pens available in the UAE market offer a subcutaneous alternative to clinic-based infusion.
Collagen Regeneration: GHK-Cu
GHK-Cu (glycine-histidine-lysine copper tripeptide) stimulates fibroblast proliferation, upregulates collagen and elastin synthesis, and activates matrix metalloproteinases that clear damaged extracellular matrix. Cosmetic and wound-healing studies apply concentrations of 0.01β2% topically once or twice daily to localised skin regions, with injectable protocols using 1β10 mg per session in experimental settings.
The compound's dual role in tissue repair and anti-inflammatory signalling makes it relevant to both skin longevity and systemic regeneration research. A broader overview of its collagen-specific applications appears in the GHK-Cu copper tripeptide section of this site.
Mitochondrial Biogenesis: MOTS-C
MOTS-C is a mitochondria-derived peptide that activates AMPK (adenosine monophosphate-activated protein kinase) and PGC-1Ξ± signalling, two pathways governing mitochondrial biogenesis, fatty acid oxidation, and metabolic flexibility. Rodent studies from 2023β2025 show improved insulin sensitivity, exercise capacity, and stress resistance at doses of 5β10 mg/kg. Early human pilot work has explored subcutaneous doses of 5β20 mg per injection, though randomised controlled trial data in healthy ageing populations remain absent as of 2026.
Human safety profiles for all three peptides rest on limited data. NAD+ infusions at 500 mg or above produce flushing, chest tightness, and nausea in a subset of participants; slowing the infusion rate typically attenuates these effects. GHK-Cu at cosmetic concentrations shows mostly mild local irritation. MOTS-C preclinical and pilot data have not identified major acute toxicity, though long-term human safety is uncharacterised.
Best Longevity Peptides Available in the UAE, 2026 Pricing & Comparison
Six longevity peptides with verified or estimated 2026 pricing are compared below. Stock status and format notes follow each entry.
| Peptide | Mechanism | Research Dosage Range | AED Price (2026) | Format | Stock Status |
|---|---|---|---|---|---|
| NAD+ 1,000 mg | SIRT1/PARP activation; NAD+ repletion for DNA repair and mitochondrial function | 250β1,000 mg per infusion; ~1 g/month subcutaneous | AED 1,210 | Pre-mixed pen; no reconstitution required | In stock, see NAD+ peptide pens |
| GHK-Cu 50 mg | Collagen I/III upregulation; MMP modulation; anti-inflammatory signalling | 0.01β2% topical; 1β10 mg/session injectable | AED 495 | Pre-mixed pen (injectable); topical serums also available | Unverified UAE stock, international vendors ship to UAE |
| MOTS-C 32 mg | AMPK and PGC-1Ξ± activation; mitochondrial biogenesis; metabolic flexibility | 5β20 mg/injection subcutaneous (pilot human data) | Price unverified in UAE as of 2026 | Lyophilised vial (requires reconstitution); no confirmed pen format | Unverified UAE stock |
| Epithalon 10 mg | Telomerase activation; pineal gland peptide regulating circadian and immune function | 5β10 mg/day subcutaneous, 10-day course (preclinical basis) | Price unverified in UAE as of 2026 | Lyophilised vial (requires reconstitution) | Unverified UAE stock |
| BPC-157 5 mg | Angiogenesis promotion; gut-brain axis repair; tendon and connective tissue regeneration | 250β500 mcg/day subcutaneous or oral (rodent-derived protocols) | Price unverified in UAE as of 2026 | Lyophilised vial (requires reconstitution) | Unverified UAE stock |
Notes on Pricing and Format
NAD+ 1,000 mg is the only peptide in this comparison with a confirmed AED price (AED 1,210) and a pre-mixed pen format that requires no bacteriostatic water or separate reconstitution. The AED 495 figure for GHK-Cu 50 mg pen is a listed price; UAE-specific stock has not been independently confirmed as of 2026, and buyers should verify availability before ordering. International vendors quoting USD $380β599 for NAD+ pens convert to approximately AED 1,395β2,200 at 2025β2026 exchange rates, which makes the AED 1,210 figure competitive if confirmed.
MOTS-C, Epithalon, and BPC-157 are available internationally as lyophilised research vials, not pre-mixed pens. Reconstitution requires bacteriostatic water and sterile technique. None carry a verified UAE-specific AED price as of 2026.
Regulatory Note
All five peptides listed above are classified as research compounds in the UAE. MOHAP (Ministry of Health and Prevention) and the Department of Health β Abu Dhabi require medicinal products to be registered before retail sale; unregistered injectable peptides cannot be legally marketed as therapies to the public. Buyers importing internationally should confirm customs documentation, cold-chain compliance, and MOHAP labelling requirements (Arabic and English text, batch number, expiry date, storage conditions) before shipment.
For collagen-specific applications of GHK-Cu, the GHK-Cu copper tripeptide page covers topical protocols and skin regeneration research in detail.
NAD+ Peptide Pens: Cellular Energy & Mitochondrial Support
NAD+ levels decline by approximately 50% between the ages of 40 and 60, a reduction that directly impairs sirtuin activity, mitochondrial biogenesis, and DNA repair capacity. That single biochemical shift underlies much of the metabolic slowdown associated with ageing, making NAD+ repletion one of the most mechanistically grounded targets in current longevity research.
The decline works through a specific pathway. As intracellular NAD+ falls, SIRT1 and SIRT3 (the sirtuins that regulate mitochondrial quality control) lose their substrate and become less active. Mitochondria accumulate damage, ATP output drops, and cells shift toward less efficient energy pathways. Restoring NAD+ availability reverses this cascade in preclinical models and, in early human data, correlates with improved metabolic flexibility.
The NAD+ 1000 mg pen addresses this directly. It arrives pre-filled with 1,000 mg of NAD+ and offers selectable dose increments of 10, 20, or 30 mg per subcutaneous injection, allowing researchers to follow graduated protocols without reconstitution or separate bacteriostatic water. Commercial dosing guidance from multiple pen-format vendors suggests a loading phase of one dose daily for three days, followed by every-other-day administration, totalling roughly 1 g per month. These are manufacturer protocols, not peer-reviewed dose-finding trials.
Reported adverse effects in research and clinic settings include flushing, nausea, chest tightness, and headache, most commonly at higher doses or faster infusion rates. Slowing the administration rate reduces these effects in clinical reports. Long-term safety data for chronic high-dose use remain limited, and some 2023β2025 mechanistic papers note theoretical concerns around immune surveillance at elevated NAD+ concentrations, though no clear human risk signal has been established.
Pricing for the pen is AED 1,210.00 as of 2026, which sits at the lower end of the AED 1,395β2,200 range derived from international USD-denominated listings at current exchange rates. Researchers whose primary interest is collagen regeneration rather than mitochondrial energy should see the GHK-Cu copper tripeptide page, which covers topical and injectable protocols in detail.
GHK-Cu Copper Tripeptide: Collagen & Tissue Regeneration
GHK-Cu (glycine-histidine-lysine copper complex) stimulates collagen I and III synthesis in dermal fibroblasts, accelerates wound healing, and improves skin elasticity by upregulating matrix metalloproteinases and their inhibitors in a coordinated remodelling cycle. Cosmetic and wound-healing studies applying 0.01β2% GHK-Cu formulations once or twice daily to localised skin regions consistently report reduced fine lines, improved barrier function, and measurable increases in dermal collagen density.
For injectable research protocols, GHK-Cu is typically used in the 1β10 mg per session range, though this remains far less standardised than topical application. Systemic adverse events at cosmetic concentrations are rare; the most commonly reported effects in topical trials are mild local irritation, transient redness, or itching. Injectable GHK-Cu systemic safety data remain limited, so researchers should treat that route with appropriate caution.
The GHK-Cu copper tripeptide pre-mixed formulation removes the reconstitution step entirely, eliminating bacteriostatic water preparation and reducing handling error. Current pricing for the 50 mg pre-mixed format is AED 495.00 as of 2026. No UAE-specific pen listing with independently verified AED pricing was located in 2024β2026 sources, so this figure should be confirmed at point of purchase.
Researchers whose primary interest is mitochondrial energy rather than collagen regeneration may find the NAD+ peptide pens more directly relevant to their protocols.
MOTS-C Peptide: Mitochondrial Biogenesis & Metabolic Health
MOTS-C (mitochondrial open reading frame of the 12S rRNA-c) is a mitochondria-derived peptide that activates AMPK and PGC-1Ξ± signalling to drive mitochondrial biogenesis, improve insulin sensitivity, and enhance cellular stress resistance.
Unlike nuclear-encoded peptides, MOTS-C is transcribed directly from mitochondrial DNA, positioning it as an endogenous regulator of metabolic homeostasis rather than an exogenous hormone analogue. Circulating MOTS-C levels decline with age in both rodent models and human observational cohorts, linking its depletion to the metabolic inflexibility characteristic of biological ageing.
Rodent studies published between 2023 and 2025 consistently show that exogenous MOTS-C at 5β10 mg/kg (intraperitoneal) several times per week activates AMPK and upregulates PGC-1Ξ±, producing measurable increases in mitochondrial density, improved glucose uptake, and greater exercise capacity in models of metabolic syndrome. Early human pilot work has explored subcutaneous doses of 5β20 mg per injection, with preliminary signals around metabolic flexibility and exercise performance, though no randomised controlled trial in healthy ageing populations has been completed as of 2026. All dosing figures here reflect research protocol ranges, not clinical recommendations.
No independently verified AED price or confirmed UAE stock listing for a Body Pharm MOTS-C 32 mg pen was located in 2024β2026 sources. Pricing and availability should be confirmed directly at point of purchase before ordering. Preclinical and early human safety data report no major acute toxicity at studied doses; transient injection-site discomfort and mild flu-like symptoms have been noted, while long-term human safety data remain limited.
Researchers combining mitochondrial support strategies may find the NAD+ peptide pens a complementary protocol, given that NAD+ depletion and MOTS-C decline share overlapping downstream effects on sirtuin function and mitochondrial integrity. For protocols targeting collagen regeneration alongside metabolic health, the GHK-Cu copper tripeptide addresses a distinct axis of cellular ageing.
How to Choose the Right Longevity Peptide for Your Research
Your primary research goal determines which peptide to prioritise first. The table below maps each goal to the corresponding peptide, typical research-protocol dose range, and the mechanism driving that application.
| Research Focus | Peptide | Typical Research Dose Range | Primary Mechanism |
|---|---|---|---|
| Cellular energy & NAD+ repletion | NAD+ | 10β30 mg subcutaneous daily (pen protocols) | Sirtuin activation, mitochondrial electron transport support |
| Collagen regeneration & skin repair | GHK-Cu | 1β10 mg per session (injectable); 0.01β2% topical | Fibroblast stimulation, TGF-Ξ² upregulation, antioxidant signalling |
| Mitochondrial biogenesis & metabolic function | MOTS-C | 5β20 mg subcutaneous per injection | AMPK/PGC-1Ξ± activation, glucose uptake, mitochondrial density |
All dose figures reflect research protocol ranges documented in 2023β2025 literature, not clinical recommendations.
Stacking Considerations
Researchers frequently combine two or three of these peptides because their mechanisms operate on distinct but complementary axes. NAD+ depletion and MOTS-C decline share downstream effects on sirtuin function and mitochondrial integrity, so pairing an NAD+ peptide pen with a MOTS-C protocol addresses both substrate availability and biogenesis signalling simultaneously. Adding GHK-Cu targets a separate axis (extracellular matrix repair and oxidative stress reduction), making it a logical third layer for protocols focused on tissue-level ageing rather than purely metabolic endpoints.
Before Committing to a Protocol
No standardised human longevity dosing exists for any of these three peptides as of 2026. Cross-reference current peer-reviewed literature and, where possible, work with a practitioner familiar with peptide research before selecting doses or combining compounds. Regulatory status in the UAE means these products are research-use items, not registered medicines, so protocol decisions rest entirely on the researcher's own due diligence.
Availability, Shipping & Regulatory Notes for UAE Customers
All three peptides covered in this article ship to Dubai, Abu Dhabi, Sharjah, and other emirates as of 2026, with delivery timeframes varying by order origin.
| Factor | Detail |
|---|---|
| Local UAE delivery (Dubai, Abu Dhabi) | 1β2 business days |
| Local UAE delivery (Sharjah, Ajman, RAK, Fujairah) | 2β4 business days |
| International express courier (DHL, FedEx) | 3β7 business days |
| Cold-chain requirement | Yes, injectable peptides require temperature-controlled shipping |
| Customs clearance impact | Public holidays and inspection delays can extend any of the above |
| Regulatory classification | Research compounds; not registered medicines under MOHAP |
| Labelling requirement (imports) | Arabic and English labelling, batch number, expiry date, storage conditions, manufacturer details |
Regulatory Status in the UAE
Research peptides are not registered therapeutic products under MOHAP or the Department of Health β Abu Dhabi. They are classified as research-use items, which means they cannot be legally marketed or sold as anti-ageing therapies or medicines without formal registration. Retail sale of unregistered injectable peptides via local e-commerce platforms sits in a regulatory grey zone; purchasing through established international research suppliers is the more transparent route.
NAD+ peptide pens and GHK-Cu copper tripeptide products listed in this article are presented strictly as research compounds. Researchers importing these items should retain documentation of ingredient origin and ensure packaging meets MOHAP labelling standards before customs submission.
Longevity Peptides: Safety, Dosage & Research Considerations
Every peptide covered in this article is a research compound, not a registered medicine under MOHAP or the Department of Health β Abu Dhabi, and none carries an approved therapeutic indication for human anti-ageing use in the UAE.
NAD+
NAD+ is generally well-tolerated at moderate doses, but clinical reports from 2023β2025 document flushing, chest tightness, nausea, headache, and anxiety during or shortly after infusions, particularly at doses of 500 mg or above or when administered rapidly. Slowing the infusion rate reduces these effects in most cases. Human IV protocols in 2024β2025 longevity studies commonly use 250β750 mg per infusion, with some clinic loading protocols reaching 1,000 mg. At-home NAD+ peptide pens follow manufacturer guidance of one dose daily for three days, then every other day, totalling approximately 1 g per month. These are product recommendations, not peer-reviewed dose-finding results. Some 2023β2025 mechanistic papers raise theoretical concerns about NAD+ repletion in the context of tumour biology and immune surveillance, though no clear human risk signal has been established.
GHK-Cu
GHK-Cu has a comparatively long safety record in cosmetic and wound-healing contexts. Topical trials applying 0.01β2% concentrations once or twice daily report only mild local irritation, transient redness, or itching; systemic adverse events at cosmetic concentrations are rare. Injectable GHK-Cu data are sparse, so systemic safety at injected doses remains uncharacterised. Researchers interested in GHK-Cu copper tripeptide for collagen regeneration protocols should treat injectable use with particular caution given the absence of standardised human dosing data.
MOTS-C
MOTS-C is the least clinically characterised of the three. Rodent studies from 2023β2025 use 5β10 mg/kg intraperitoneal injections several times per week, while small human pilot cohorts have explored subcutaneous doses of 5β20 mg per session. No major acute toxicity has been identified at studied doses, but transient injection-site discomfort, fatigue, and flu-like symptoms have been noted, and long-term human safety, carcinogenicity, and reproductive effects are not yet characterised. Randomised controlled trials in healthy ageing populations are still absent as of 2025β2026.
Consult a licensed healthcare provider before initiating any peptide protocol. Starting at the lower end of documented research ranges and monitoring for adverse responses is the standard approach across all three compounds.
Complementary Peptides & Accessories for Longevity Research
NAD+, GHK-Cu, and MOTS-C are rarely used in isolation. Most longevity research protocols combine two or more peptides to target distinct biological pathways simultaneously, from telomere maintenance to growth hormone signalling.
Epithalon
Epithalon (Epitalon) is a tetrapeptide that activates telomerase, the enzyme responsible for maintaining telomere length in somatic cells. A 2023β2025 body of preclinical work links telomerase activation via Epithalon to reduced markers of cellular senescence and extended replicative lifespan in aged tissue models. Researchers pairing Epithalon with NAD+ peptide pens are targeting both upstream NAD+ metabolism and downstream chromosomal stability within a single protocol.
Somatropin and Ipamorelin
Somatropin (recombinant human growth hormone) and Ipamorelin (a selective growth hormone secretagogue) are used in longevity research to support lean mass retention, metabolic rate, and tissue repair. These processes decline measurably after the age of 35. Ipamorelin is preferred in many research settings because it stimulates pulsatile GH release without significantly elevating cortisol or prolactin, reducing off-target hormonal interference.
Stacking and Accessories
Combining peptides with complementary mechanisms (for example, MOTS-C for mitochondrial biogenesis alongside GHK-Cu copper tripeptide for collagen regeneration) is standard practice in structured longevity protocols. Proper administration requires sterile syringes, alcohol swabs, bacteriostatic water for reconstitution, and appropriate cold-chain storage between 2β8 Β°C. The site's Accessories page stocks these consumables for UAE-based researchers, with same-day or next-day delivery available in Dubai and Abu Dhabi.
Frequently Asked Questions: Longevity Peptides in the UAE
| Question | Answer |
|---|---|
| Are longevity peptides legal in the UAE? | They are sold as international research products, not registered medicines. MOHAP and the Department of Health β Abu Dhabi regulate therapeutic peptides marketed for human use; unregistered injectables cannot be legally sold as treatments. |
| How long before results are measurable? | Protocols typically run 4β12 weeks before researchers observe changes in biomarkers such as NAD+ levels, skin collagen density, or metabolic markers. Shorter windows may show subjective changes; objective data generally require at least 8 weeks of consistent use. |
| Can multiple peptides be stacked? | Yes. Common research stacks include NAD+ peptide pens paired with MOTS-C for combined NAD+ repletion and mitochondrial biogenesis support, or NAD+ combined with GHK-Cu copper tripeptide to address both cellular energy and collagen regeneration simultaneously. |
| What is the difference between pre-mixed and powder forms? | Pre-mixed pens (such as NAD+ and GHK-Cu formats) arrive ready to inject with no preparation required. Powder (lyophilised) peptides require reconstitution with bacteriostatic water using sterile syringes and alcohol swabs before use. Consumables are available on the site's Accessories page. |
| What are the known side effects? | NAD+ infusion and injection studies from 2023β2025 report flushing, chest tightness, nausea, and headache, particularly at doses of 500 mg or above or with rapid administration. GHK-Cu topical trials note mild local irritation at cosmetic concentrations. MOTS-C preclinical and small human pilot data up to 2025 show no major acute toxicity, though injection-site discomfort has been noted. |
| Does the site ship internationally? | Primary fulfilment covers the UAE, with same-day or next-day delivery in Dubai and Abu Dhabi and 2β4 business days to other emirates including Sharjah, Ajman, and Ras Al Khaimah. International orders to the wider GCC region are available; cold-chain packaging is used for all injectable peptides, and customs clearance can add 3β7 business days for shipments outside the UAE. |
A Note on Research-Use Status
Longevity peptides sold through this site are international research products. MOHAP requires that any product marketed as a medicine in the UAE carry full registration, Arabic and English labelling, batch numbers, expiry dates, and manufacturer details. Purchasing for personal research does not constitute medical treatment, and no peptide listed here carries an approved therapeutic indication in the UAE as of 2026.
Key Takeaways
- NAD+, GHK-Cu, and MOTS-C target distinct ageing pathways: cellular energy, collagen regeneration, and mitochondrial biogenesis respectively.
- NAD+ 1,000 mg pen is the only peptide with confirmed AED pricing (AED 1,210) and pre-mixed format in the UAE market as of 2026.
- All three peptides are research compounds, not registered medicines under MOHAP; regulatory status in the UAE remains a grey zone for unregistered injectables.
- Stacking two or three peptides is standard practice in longevity research; NAD+ pairs well with MOTS-C for combined metabolic support.
- Safety data are limited: NAD+ causes flushing and nausea at high doses, GHK-Cu shows mild topical irritation, and MOTS-C long-term human safety is uncharacterised.
- Protocols typically require 4β12 weeks before measurable biomarker changes; objective results generally need at least 8 weeks of consistent use.
Next Steps
Before starting any peptide protocol, cross-reference current peer-reviewed literature (PubMed, Google Scholar) and consult a licensed healthcare provider familiar with peptide research. Confirm current AED pricing and UAE stock status directly with suppliers, as availability and cost fluctuate. For cellular energy support, start with the NAD+ peptide pens page; for collagen regeneration, see the GHK-Cu copper tripeptide section. The site's Accessories page covers sterile syringes, bacteriostatic water, and cold-chain storage supplies for your research protocol.